vendredi 25 mai 2018

Onco Actu du 25 mai 2018

1. Biologie

By forming clots in tumors, immune cells aid lung cancer's spread [UNC]

NIH study finds gut microbiome can control antitumor immune function in liver [NIH]

2. Etiologie

Pressured by industry, U.S. EPA slows formaldehyde study release: documents [Reuters]

2.5 Etiologie - Gènes

Tau Mutations May Increase Cancer Risk [AACR]

3.1 Prévention - Tabac

Money’s better than e-cigs or nicotine gum at helping smokers quit, study says [The Verge]

4.2 Dép., diag. & prono. - Génome

Researchers Demonstrate Veracyte's Sequencing Test Can Identify Benign Thyroid Nodules [Genome Web]

Two Initiatives Seek to Harmonize Tumor Mutational Burden Testing [Genome Web]

4.9 Dép., diag. & prono. - Sein

Breast screen error 'could have been spotted earlier' [BBC News]

5.1 Traitements - Pré-clinique

Tiny particles could help fight brain cancer [MIT News]

A Closed Loop [in the Pipeline]

5.12 Immunothérapies

Can Immunotherapy Succeed in Glioblastoma? [NCI]

Patient harm from ads for Opdivo and other cancer immunotherapies [HealthNewsReview]

5.12.3 Immunothérapies-combinaisons

Phase III IMblaze370 Study Did Not Meet Its Primary Endpoint of Overall Survival [ESMO]

5.12.5 Immunothérapies - Pharma

Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer [AstraZeneca]

AstraZeneca cancer drug hits second goal by extending survival [Reuters]

5.2 Pharma

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint [AbbVie]

AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks [FiercePharma]

Lilly's cancer business loses its chief just as it's leaning on oncology for growth [FiercePharma]

Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin's Lymphoma [Genmab]

5.2.1 Pharma - Partenariats

Eisai and Merck Provide Update on Supplemental New Drug Application (Snda) for Lenvatinib in First-line Unresectable Hepatocellular Carcinoma [Merck]

5.3 Traitements - FDA, EMA, NICE...

No Evidence that FDA Breakthrough-Designated Anticancer Drugs Provide Improvements in Efficacy, Safety or Novelty [ESMO]

5.4 Traitements - Economie

Hello, $200B: Super-pricey new cancer drugs drive mega increases in treatment spending [FiercePharma]

5.5.1 ASCO (général)

Brad Loncar’s ASCO18 preview: Past ASCOs point to the top drugs that will soon elbow for the Oscars of cancer R&D [EndPoints] ASCO (général) - Académiques

Fred Hutch scientists to feature health economics, next-gen immunotherapy, health disparities and more at ASCO [Fred Hutch]

6. Lutte contre les cancers

WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer [WHO]

6.1 Observation

Physical Activity in Cancer Survivors During “Re-Entry” Following Cancer Treatment [CDC]

6.10.1 Politiques (USA)

Right To Try Act Poses Big Challenge For FDA [NPR]

'Right-to-Try' Drug Law Offers No Miracle Cure [Bloomberg]

'Right to try' is an ill-considered bill [The Hill]

6.11 Patients

Cancer patient feels 'privileged to be alive' after NHS trial treatment [BBC News]

6.4 Médico-éco

How much does it cost to save a life? Sometimes treating cancer means going broke [Chicago Tribune]

6.6 Publications

University requests 20 retractions of cancer papers following probe [Retraction Watch]

Before reproducibility must come preproducibility [Nature]

6.9 Controverses

Johnson & Johnson suffers another cancer-suit loss as talc case count climbs above 9,000 [FiercePharma]

Why was Theranos so believable? Medicine needs to look in the mirror [STAT]